

Significant effects with Cerebrolysin®



Cerebrolysin® reduces inflammation!



Cerebrolysin® increases tight junctions!



Title: Therapeutic effect of Cerebrolysin on reducing impaired cerebral endothelial cell permeability Author: Teng, Hua, et al. ournal: NeuroReport 32.5 (2021): 359-366

Copyright © 2021 by EVER Neuro Pharma GmbH, Oberburgau 3, 4866 Unterach, Austria, All rights reserved. No part of this brochure may be reproduced in any form or by any electronic or mechanical mean including information storage and retrieval systems, without permission in writing from the publisher. Cerebrolysin is a registered trademark of EVER Neuro Pharma GmbH, 4866 Unterach, Austria. ABBRE-VIATED PRESCRIBING INFORMATION - Cerebrolysin. Name of the medicinal product: Cerebrolysin - Solution for injection. Qualitative and quantitative composition: One ml contains 215.2 mg of Cerebrolysin concentrate in aqueous solution. List of excipients: Sodium hydroxide and water for injection. Therapeutic indications: For treatment of cerebrovascular disorders. Especially in the following indications: Senile dementia of Alzheimer's type. Vascular dementia. Stroke. Craniocerebral trauma (commotio and contusio). Contraindications: Hypersensitivity to one of the components of the drug, epilepsy, severe renal impairment. Marketing Authorisation Holder: EVER Neuro Pharma GmbH, A-4866 Unterach. Only available on prescription and in pharmacies. More information about pharmaceutical form, poster and method of administration, special warnings and precautions for use, interaction with other medicinal products and other forms of interaction, fertility, pregnancy and lactation, effects on ability to drive and use machines, undesirable effects, overdose, pharmacodynamics properties, pharmacokinetic properties, preclinical safety data, incompatibilities, shelf life, special precautions for storage, nature and contents of the container and special precautions for disposal is available in the summary of product characteristics. (Reference SPC – CCDS Version 2.0/03.06.2016) EVER Neuro Pharma GmbH, Oberburga 3, 4866 Unterach, Austria, www.everpharma.com, www.cerebrolysin.com

STROKE TBI DEMENTIA

Cerebrolysin improves BBB integrity

Reduction of tPA/fibrin-impaired BBB permeability

Teng, Hua, et al. "Therapeutic effect of Cerebrolysin on reducing impaired cerebral endothelial cell permeability." NeuroReport 32.5 (2021): 359-366.









Reconnecting Neurons. Empowering for Life.

tPA/fibrin-impaired BBB permeability




Risk of intracerebral hemorrhage!

Cerebrolysin® improves cerebral endothelial cell integrity



Cerebrolysin® significantly reduction



BBB gets tighter again with Cerebrolysin[®]!

of tPA/fibrin augmented permeability **by more than 50%**